RNAi
February 4, 2022
Alnylam Receives Prestigious Massachusetts Economic Impact Award
We are pleased and honored to have been named a Gold Team Massachusetts Economic Impact Award winner for 2022 by MassEcon.
Read More ›
May 1, 2020
John Maraganore on the "I Am BIO" Podcast: Destroying COVID's Genome
Our CEO John Maraganore recently spoke with Biotechnology Innovation Organization (BIO) CEO and Chairman Jim Greenwood on the "I Am BIO" podcast.
Read More ›
October 1, 2019
The Importance of Ensuring Quality in a New Class of Medicines
In Product Quality, we have a truly big picture view of the medicines we’re making to ensure they are compliant with good manufacturing practices and...
Read More ›
October 1, 2019
Building for Our Future
Why would a company without a commercially approved medicine decide to build a significant manufacturing facility? Why not continue to rely on contract...
Read More ›
May 12, 2019
What is RNAi and How Do RNAi Therapeutics Work?
What is RNAi? This video explains how Alnylam is leading the translation of RNAi to create an entirely new class of innovative medicines to treat disease.
Read More ›
September 10, 2018
A Triumph of Perseverance Over Interference [Nature Biotechnology]
The following Editorial appeared in Nature Biotechnology (36,775 2018) on September 6, 2018...
"A triumph of perseverance over interference"...
Read More ›
August 11, 2018
New Kind of Drug, Silencing Genes, Gets FDA Approval [Wall Street Journal]
The following article appeared in The Wall Street Journal on August 10, 2018...
"New Kind of Drug, Silencing Genes, Gets FDA Approval"...
Read More ›
April 30, 2018
Hunting for Targets: Bringing RNAi to Humans
Evolution is a powerful force, and Mother Nature is often a great source of inspiration for drug hunters like me. If you look at the history of successful...
Read More ›
April 30, 2018
Building to Scale: Raising RNAi Therapeutics From Infancy
When I joined Alnylam in 2004, one of our early challenges was figuring out how to manufacture and deliver RNAi therapeutics for our clinical trials. The...
Read More ›
